Micromotor-Enabled Active Hydrogen and Tobramycin Delivery for Synergistic Sepsis Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844 (Electronic) Linking ISSN: 21983844 NLM ISO Abbreviation: Adv Sci (Weinh) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Weinheim : WILEY-VCH, [2014]-
    • Subject Terms:
    • Abstract:
      Sepsis is a highly heterogeneous syndrome normally characterized by bacterial infection and dysregulated systemic inflammatory response that leads to multiple organ failure and death. Single anti-inflammation or anti-infection treatment exhibits limited survival benefit for severe cases. Here a biodegradable tobramycin-loaded magnesium micromotor (Mg-Tob motor) is successfully developed as a potential hydrogen generator and active antibiotic deliverer for synergistic therapy of sepsis. The peritoneal fluid of septic mouse provides an applicable space for Mg-water reaction. Hydrogen generated sustainably and controllably from the motor interface propels the motion to achieve active drug delivery along with attenuating hyperinflammation. The developed Mg-Tob motor demonstrates efficient protection from anti-inflammatory and antibacterial activity both in vitro and in vivo. Importantly, it prevents multiple organ failure and significantly improves the survival rate up to 87.5% in a high-grade sepsis model with no survival, whereas only about half of mice survive with the individual therapies. This micromotor displays the superior therapeutic effect of synergistic hydrogen-chemical therapy against sepsis, thus holding great promise to be an innovative and translational drug delivery system to treat sepsis or other inflammation-related diseases in the near future.
      (© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.)
    • References:
      Angew Chem Int Ed Engl. 2017 Sep 11;56(38):11399-11403. (PMID: 28643857)
      JAMA. 2016 Feb 23;315(8):801-10. (PMID: 26903338)
      Adv Sci (Weinh). 2023 Nov;10(33):e2303759. (PMID: 37818787)
      Int J Biol Sci. 2019 May 11;15(6):1261-1275. (PMID: 31223285)
      ACS Appl Mater Interfaces. 2018 Oct 17;10(41):35099-35107. (PMID: 30246523)
      Shock. 2010 Jul;34(1):90-7. (PMID: 19997046)
      Br J Anaesth. 2011 Jul;107(1):57-64. (PMID: 21596843)
      Mol Cell Biochem. 2014 Jul;392(1-2):117-24. (PMID: 24652103)
      Reproduction. 2020 Feb;159(2):R83-R96. (PMID: 31600732)
      Nano Lett. 2021 Mar 10;21(5):1982-1991. (PMID: 33624495)
      ACS Nano. 2019 Jan 22;13(1):429-439. (PMID: 30588798)
      Adv Mater. 2016 Jun;28(21):4084-9. (PMID: 27003908)
      Nat Med. 2007 Jun;13(6):688-94. (PMID: 17486089)
      Sci Transl Med. 2015 Sep 2;7(303):303ra140. (PMID: 26333936)
      Angew Chem Int Ed Engl. 2013 Jul 1;52(27):7000-3. (PMID: 23703837)
      ACS Nano. 2023 May 9;17(9):8551-8563. (PMID: 37129445)
      Angew Chem Int Ed Engl. 2017 Feb 13;56(8):2156-2161. (PMID: 28105785)
      Sci Robot. 2017 Mar 15;2(4):. (PMID: 31552379)
      Cleve Clin J Med. 2020 Jan;87(1):53-64. (PMID: 31990655)
      Crit Care. 2010;14(4):230. (PMID: 20804578)
      Angew Chem Int Ed Engl. 2017 Oct 9;56(42):12935-12939. (PMID: 28816386)
      Crit Care Med. 1997 Jul;25(7):1115-24. (PMID: 9233735)
      Nat Rev Immunol. 2017 Jul;17(7):407-420. (PMID: 28436424)
      ACS Nano. 2018 Aug 28;12(8):8397-8405. (PMID: 30059616)
      Small. 2020 May;16(20):e1907150. (PMID: 32329580)
      Crit Care. 2011;15(5):230. (PMID: 21996422)
      Lancet. 2020 Jan 18;395(10219):200-211. (PMID: 31954465)
      Sci Adv. 2020 May 29;6(22):eaay7148. (PMID: 32523983)
      Parasit Vectors. 2017 May 8;10(1):222. (PMID: 28482922)
      Macromol Biosci. 2019 Feb;19(2):e1800376. (PMID: 30549406)
      Nat Commun. 2017 Aug 16;8(1):272. (PMID: 28814725)
      Virulence. 2014 Jan 1;5(1):36-44. (PMID: 23774844)
      Nanoscale. 2013 Jun 7;5(11):4696-700. (PMID: 23640547)
      Trends Microbiol. 2011 Apr;19(4):198-208. (PMID: 21296575)
      Nat Protoc. 2009;4(1):31-6. (PMID: 19131954)
      ACS Nano. 2020 Aug 25;14(8):10324-10336. (PMID: 32806029)
      J Surg Res. 2012 Nov;178(1):e9-16. (PMID: 22475349)
      Nat Commun. 2020 Jul 7;11(1):3384. (PMID: 32636379)
      Med Gas Res. 2012 Jan 24;2:1. (PMID: 22273079)
      Adv Mater. 2016 Feb 3;28(5):832-7. (PMID: 26619085)
    • Grant Information:
      2022YFA1206900 National Key Research and Development Program; 22175083 National Natural Science Foundation of China; 51973241 National Natural Science Foundation of China
    • Contributed Indexing:
      Keywords: drug delivery; hydrogen; micromotor; sepsis; synergistic therapy
    • Accession Number:
      VZ8RRZ51VK (Tobramycin)
      0 (Anti-Bacterial Agents)
    • Publication Date:
      Date Created: 20231011 Date Completed: 20231127 Latest Revision: 20231127
    • Publication Date:
      20231128
    • Accession Number:
      PMC10667834
    • Accession Number:
      10.1002/advs.202303759
    • Accession Number:
      37818787